# A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

> **NCT01357161** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 136 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** adavosertib
- **DRUG:** Placebo
- **DRUG:** paclitaxel
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT01357161
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-26
- **Primary completion:** 2016-08-08
- **Final completion:** 2016-08-08
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01357161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01357161, "A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01357161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*